We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 205% above its sector, the market expects faster growth.
ShanXi C&Y Pharmaceutical Group Co., Ltd. is a global pharmaceutical enterprise dedicated to the research, development, production, and distribution of a diverse range of medicines. Its operations span key markets including China, the United States, and Hong Kong, alongside other international regions. The company's extensive product catalog features specialized solutions for maternal and infant care, urological health, and infectious diseases, as well as traditional Chinese remedies and dermatological treatments. Additionally, it diversifies its offerings with tea bag products. Founded in 2005, the organization underwent a name change in September 2014, evolving from Shanxi C&Y Pharmaceutical Co., Ltd. to its current designation. ShanXi C&Y Pharmaceutical Group Co., Ltd. maintains its corporate headquarters in Shanghai, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 300254.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
